ReviewCureus2024
Artificial Intelligence in Dry Eye Disease: A Narrative Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dry Eye Disease: From Mechanisms to Management and Future Directions.Journal of clinical medicine · 2026Review
- Artificial Intelligence Application in Cornea and External Diseases.Diagnostics (Basel, Switzerland) · 2025Review
- Modern diagnostics for dry eye disease: implications for rheumatology.Reumatologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a multifactorial condition affecting millions worldwide, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. The complexity of its diagnosis and management, driven by the diversity of symptoms and underlying causes, presents significant challenges to clinicians. Artificial intelligence (AI) has emerged as a transformative tool in healthcare, offering potential solutions to these challenges through its data analysis, pattern recognition, and predictive modeling capabilities. This narrative review explores the role of AI in diagnosing, treating, and managing dry eye disease. AI-driven tools such as machine learning algorithms, imaging technologies, and diagnostic platforms are examined for their ability to enhance diagnostic accuracy, personalize treatment approaches, and optimize patient outcomes. Furthermore, the review addresses the limitations of AI technologies in ophthalmology, including the need for robust clinical validation, data privacy concerns, and the ethical considerations of integrating AI into clinical practice. The findings suggest that while AI holds promise for improving the care of patients with DED, ongoing research and development are crucial to realizing its full potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.